Healthcare focused fund that acquires drug royalties and provides launch financing to middle market biopharma companies in the form of synthetic royalties or structured credit. A newer pool of capital is dedicated to earlier stage investments with higher "science" or clinical risk. Credit / royalty target returns ~13-15%, early stage target returns 20%+.